Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
YKL-05-099 is an inhibitor of salt-inducible kinase 2 (SIK2; IC50 = 0.04 µM for the human enzyme).1 It is selective for SIK2 over a panel of 141 kinases at 1 µM but also inhibits 14 other kinases, including SIK3, Ephrin receptors, and Src. YKL-05-099 increases IL-10 production in zymosan A-induced isolated mouse bone marrow-derived dendritic cells (BMDCs; EC50 = 0.46 µM), as well as decreases TNF-α, IL-6, and IL-12p40 levels and increases IL-1β levels in LPS-stimulated BMDCs when used at a concentration of 1 µM. It inhibits the proliferation of MOLM-13 leukemia cells (IC50 = 0.24 µM).2 In vivo, YKL-05-099 (10 µmol/kg) increases the bone formation rate and number of femoral osteoblasts and decreases the number of femoral osteoclasts in mice.3
WARNING This product is not for human or veterinary use.
1. Development of chemical probes for investigation of salt-
2. Salt-
3. SIKs control osteocyte responses to parathyroid hormone. Nat. Commun. 7, 13176 (2016).